ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa

Donate and help Drugs for Neglected Diseases initiative (DNDi) make medical history:

Outstanding statements on the ANTICOV study:

Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention: There is a need for large clinical trials in Africa for COVID-19 to answer research questions that are specific to an African context’.

Dr Borna Nyaoke-Anoke, Senior Clinical Project Manager at DNDi: ‘It is heartening to see so many African countries collaborate to get much-needed answers about our unique COVID-19 patient needs’.

Dr Nathalie Strub-Wourgaft, Director of COVID-19 Response for DNDi and PI of the study: ‘The ANTICOV consortium is a broad partnership bringing African scientific leaders and global R&D organizations together to respond to an urgent unmet medical need. Collaboration is the only way to provide robust scientific responses to these research questions’.

Description of the Study:

  • Title: An open-label, multi-centre, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19.
  • Principal Investigator: Dr Nathalie Strub-Wourgaft.
  • Countries of Implementation: Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda.
  • Study Population: Up to 3000 adults over 18 years with mild or moderate COVID-19.
  • Study Type: Interventional clinical trial of treatment, in phase III.
  • Design: At first, the trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries. Subsequently, new treatments as medicines currently used to treat malaria, HIV, hepatitis C, parasitic infections, and certain cancers, will be added to the trial as evidence of their potential for mild-to-moderate cases emerges.
  • Methods: Antimalarials and antivirals treatments.

Objectives of the Study:

Principal Objective: The primary objective is to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease.

Secondary Objectives:
(1) To identify treatments that could be used to treat mild and moderate cases of COVID-19, to stop the disease from getting more serious.
(2) To find a treatment to help avoid mass hospitalizations in African health systems with limited intensive care facilities.

More about this Study:

Added value: The ANTICOV clinical trial aims to respond to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in Africa. 

This COVID-19 study will be carried out at 19 sites in 13 countries by the ANTICOV consortium, which includes 26 prominent African and global research and development (R&D) organizations, coordinated by DNDi

Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW banking group and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland. 

Dndi Icon
German Federal Ministry of Education and Research (BMBF) is funding ANTICOV study about covid-19 in Africa
Starr Foundation is funding ANTICOV study about covid-19 in Africa
Kfw is funding ANTICOV study about covid-19 in Africa
Unitaid is funding ANTICOV study about covid-19 in Africa
Edctp is funding ANTICOV study about covid-19 in Africa

Other Clinical Trials:

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

CHRONOS19: Hematologic diseases and COVID-19

A Russian study to determine the severity and lethality of COVID-19 infection in patients with hematologic diseases.

Machine Learning Models as Diagnostic Tools for COVID-19

Clinical trial that studies the development of alternative diagnostic tools that reliably assess COVID-19 infection, and that are low cost and easy to administer to…

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a…

Influenza Vaccination, ACEI and ARB in the Evolution of COVID-19

A study to determine if influenza vaccination or ACEI or ARB medication has effects on COVID-19.

PRIORITISE Study: Oxygen Requirement In Non-Severe COVID-19 Patients

The PRIORITISE study aims to identify clinical and biochemical prognostic markers in adults with non-severe COVID-19.

Progesterone for the Treatment of COVID-19

Can sex hormones help men survive COVID-19? This study assesses the safety and efficacy of progesterone for the treatment of COVID-19 in hospitalized men.

Predictive Factors COVID-19 Patients

A monocentric retro-prospective observational study that analyzes predictive clinical response factors in COVID-19 positive patients hospitalized at San Gerardo Hospital in Monza.

PanCOVID19: Evaluating Pharmacological Treatments

Open, randomized, adaptive, phase III clinical trial study to evaluate the efficacy of various pharmacological alternatives in the treatment of severe infection in COVID-19 pediatric…

AstraZeneca Study of COVID-19 Vaccine Candidate AZD1222

Clinical trial designed to determine if the vaccine candidate, AZD1222, can prevent symptomatic COVID-19.